David D'agate, MD
Cardiology · Smithtown, NYNPI 1790784395
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $61,952 of the $69,261 with a category attached, or 89.4%. Amgen accounts for 94.0% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $35,507, more than ten times the $157 reported in 2019. Among cardiology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 315 payments — averaging $219.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$65K
- Novartis$1K
- Esperion Therapeutics, Inc.$717
- Novo Nordisk$350
- Boehringer Ingelheim$321
- Daiichi Sankyo Inc.$221
- plus $1K from 17 others
What the payments were for
- Speaking & faculty fees$61,95289%
- Travel & lodging$1870%
- Food & beverage$7,10810%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 83 | $65,101 |
| Novartis | 100 | $1,420 |
| Esperion Therapeutics, Inc. | 25 | $717 |
| Novo Nordisk | 24 | $350 |
| Boehringer Ingelheim | 16 | $321 |
| Daiichi Sankyo Inc. | 12 | $221 |
| Pfizer | 10 | $182 |
| Heartflow, Inc. | 6 | $154 |
| AstraZeneca | 8 | $130 |
| E.r. Squibb & Sons, L.L.C. | 5 | $96 |
| Abbott | 4 | $94 |
| Boston Scientific | 3 | $81 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $79 |
| Regeneron Healthcare Solutions, Inc. | 3 | $51 |
| Lilly USA, LLC | 2 | $43 |
| Merck | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 3 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Cvrx, Inc. | 1 | $34 |
| Lexicon Pharmaceuticals, Inc. | 1 | $24 |
| Bridgebio Pharma, Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $18 |
| Philips North America LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$69,261 in reported general payments places this provider in the 95th percentile of 112 cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 342 | $461,064 |
| Repatha SureclickEvolocumab | 415 | $416,400 |
| JardianceEmpagliflozin | 74 | $80,079 |
| EntrestoSacubitril/Valsartan | 45 | $75,806 |
| XareltoRivaroxaban | 51 | $67,511 |
| FarxigaDapagliflozin Propanediol | 42 | $64,715 |
| MultaqDronedarone Hcl | 25 | $49,700 |
| Praluent PenAlirocumab | 53 | $46,457 |
| BrilintaTicagrelor | 30 | $34,368 |
| Ezetimibe | 1,013 | $30,764 |
| NexletolBempedoic Acid | 25 | $23,823 |
| Rosuvastatin Calcium | 1,088 | $16,418 |
| NexlizetBempedoic Acid/Ezetimibe | 17 | $14,716 |
| VascepaIcosapent Ethyl | 31 | $14,488 |
| Metoprolol Succinate | 766 | $12,774 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $182 | $461,064342 claims |
| AstraZenecaFarxiga, Brilinta | $130 | $99,08372 claims |
| Boehringer IngelheimJardiance | $321 | $80,07974 claims |
| NovartisEntresto | $1,420 | $75,80645 claims |
| Johnson & JohnsonXarelto | $18 | $67,51151 claims |
| Sanofi-aventis U.S. LLCMultaq | $35 | $49,70025 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $717 | $38,53842 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 112 cardiology providers in New York.
Other cardiology in Smithtown
- Michael HappesSmithtown$30K
- Saikrishna PatibandlaSmithtown$3K
- Rakesh PatelSmithtown$1K
- Eileen BishopSmithtown$1K
- Felix OviasuGarden City$150K
- Michael SiegalNew York$43K
- Michael AvaricioOzone Park$41K
- Bimalkumar BrahmbhattAmityville$31K
- Meyer AbittanRoslyn$28K
- Perminder GrewalStony Point$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.